Exact Mass: 325.2075386
Exact Mass Matches: 325.2075386
Found 94 metabolites which its exact mass value is equals to given mass value 325.2075386,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
dinor-Levomethadyl acetate
dinor-Levomethadyl acetate is a metabolite of levomethadyl acetate. Levacetylmethadol, levomethadyl acetate, Orlaam (trade name) or levo-α-acetylmethadol (LAAM) is a synthetic opioid similar in structure to methadone. It has a long duration of action due to its active metabolites. (Wikipedia)
Farnesylcysteine
In patients with chronic fatigue syndrome (CFS) we found increased IgM levels to S-farnesyl-L-cysteine. S-farnesyl-L-cysteine plays a key role in regulating cell growth, differentiation and apoptosis through RAS protein activity. The latter depends on their anchorage to the inner surface of the plasma membrane, which is promoted by their common carboxy-terminal S-farnesyl-cysteine. The presence of antibodies to S-farnesyl-L-cysteine suggest that RAS functions may have undergone damage by oxidative/nitrosative stress, causing disturbed functional activity in the regulation of cell growth. (PMID 17159817).
Norpropoxyphene
Norpropoxyphene is a major metabolite of the opioid analgesic drug dextropropoxyphene, and is responsible for many of the side effects associated with use of this drug, especially the unusual toxicity seen during dextropropoxyphene overdose. It has weaker analgesic effects than dextropropoxyphene itself, but is a relatively potent pro-convulsant and blocker of sodium and potassium channels, particularly in heart tissue, which produces prolonged intracardiac conduction time and can lead to heart failure following even relatively minor overdoses. The toxicity of this metabolite makes dextropropoxyphene up to 10 times more likely to cause death following overdose compared to other similar mild opioid analgesics, and has led to dextropropoxyphene being withdrawn from the market in some countries.
Aprofene
D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent
Isoleucyl-prolyl-proline
L-Proline, 1-(1-L-leucyl-L-prolyl)-
Ifenprodil
D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018691 - Excitatory Amino Acid Antagonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists C - Cardiovascular system > C04 - Peripheral vasodilators > C04A - Peripheral vasodilators COVID info from DrugBank, clinicaltrial, clinicaltrials, clinical trial, clinical trials D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
Mrz 2266 BS
D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D009292 - Narcotic Antagonists
ifenprodil
D018377 - Neurotransmitter Agents > D018683 - Excitatory Amino Acid Agents > D018691 - Excitatory Amino Acid Antagonists C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists C - Cardiovascular system > C04 - Peripheral vasodilators > C04A - Peripheral vasodilators COVID info from DrugBank, clinicaltrial, clinicaltrials, clinical trial, clinical trials D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
1,1-diphenyl-2,2-piperidine-2,6-diyl-bis-ethanol|2,6-Bis-(beta-hydroxy-phenaethyl)-piperidin|2,6-bis-(beta-hydroxy-phenethyl)-piperidine|Norlobelamidin|Norlobelanidin
1-methyl-2-[7?-oxo-(E)-5?-undecenyl]-4(1H)-quinolone|euocarpine A
1-methyl-2-[6?-oxo-(E)-7?-undecenyl]-4(1H)-quinolone|euocarpine B
9-(6-methoxynaphthalen-2-yl)oxy-3-azaspiro[5.5]undecane
etafenone
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist C - Cardiovascular system > C01 - Cardiac therapy > C01D - Vasodilators used in cardiac diseases D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
9-Amino(9-deoxy)epi-diquinidine trihydrochloride
C20H27N3O (325.21540120000003)
SR-59230A free base
D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists
Pro-Pro-Ile
D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones
2-amino-3-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trienyl]sulfanylpropanoic acid
N-(1-adamantyl)-6-(3,5-dimethyl-1-pyrazolyl)-1,2,4,5-tetrazin-3-amine
2-[4-(heptylthio)-2,5-dimethoxyphenyl]-N-methylethanamine
2-(2,3-Dihydroxybutoxy)-N-(2-(diethylamino)ethyl)-3-pyridinecarboxamide
S-[(2E,6E)-farnesyl]-L-cysteine zwitterion
An amino acid zwitterion arising from transfer of a proton from the carboxy to the amino group of S-[(2E,6E)]-farnesyl-L-cysteine; major species at pH 7.3.
S-[(2E,6E)-farnesyl]-L-cysteine
An S-farnesyl-L-cysteine where the C=C double bonds at the 2- and 6-positions both have (E)-configuration.
SPHP(14:0)
C14H32NO5P (325.20179920000004)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved